View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, Sept. 17 (HealthDay News) -- A substantial proportion of women treated with placebo for female sexual arousal disorder (FSAD) experience clinically significant sexual function improvements, and changes in sexual behavior appear to be predictive of outcomes in sexual function, according to research published online Sept. 16 in the Journal of Sexual Medicine.
Andrea Bradford, Ph.D., of the Houston Center for Quality of Care and Utilization Studies, and Cindy M. Meston, Ph.D., of the University of Texas at Austin, analyzed data from 50 subjects in the placebo arm of a 12-week, randomized controlled trial for FSAD to determine the nature and predictors of placebo response.
The researchers found that a third of the placebo recipients experienced a clinically significant magnitude of change post-treatment. Improvement in symptoms was strongly associated with the frequency of satisfying sexually encounters during treatment, though this relationship varied significantly among participants. The authors write that changes in sexual behavior during the trial seemed to be a more important predictor of outcome than age or symptom severity at baseline.
"Our work suggests that there is a close relationship between increased satisfying sexual behavior and sexual function outcomes in women receiving placebo treatment for sexual dysfunction, although there appears to be individual variation in the strength of this relationship. Promising targets for future study include evaluation of outcomes in waitlist/natural history versus placebo treatment groups, testing of psychosocial predictor variables as moderators of placebo response, the influence of partner behavior and expectancies on outcomes, and the effects of behavior change manipulations on outcomes," the authors conclude.
The trial was sponsored by Eli Lilly/ICOS Corporation.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top